E-cadherin can bind to EGFR and regulate its activation leading to either anti- or pro-tumorigenic outcomes depending on the stage of HCC progression and the status of Wnt/β-catenin signaling [151]. This evidence concerns the gene CDH1 and hepatocellular carcinoma.